Osteoporosis, Clinical Reviews in Bone and Mineral Metabolism | DeepDive (2023)

New treatments for the growing plague of brittle bones

Wilson, JF

The global problem of osteoporosis: insights from epidemiology

Riggs, BL; Melton, LJ

Hip fractures in the elderly: a comprehensive view

Kuiper, C; Campion, G; Melton, LJ

Osteoporosis - a global problem and its impact in Asia

Lau, EM

Epidemiology and outcomes of osteoporotic fractures

Cummings, SR; Melton, LJ

osteoporosis

Lee, CA; Einhorn, TA

Bone matrix proteins: function, regulation and their relationship to osteoporosis

Young, M.F

Invited review: pathogenesis van osteoporosis

Seeman, E

Regulation of bone remodeling and emerging novel drugs for osteoporosis and osteolytic bone metastases

Boyce, φίλε? Xing, L; Shakespear, W.

Genetic control of osteoporosis susceptibility

Ralston, SH

Osteoclast differentiation and activation

Boyle, WJ; Simonet, WS; Lacy, DL

Self-assessment program for pharmacotherapy

Follin, SL

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKI

Yasuda, Η., Shima, Ν;

Osteoprotegerin ligand (OPGL) directly activates mature osteoclasts

Burgess, TL; Qian, Y; Kaufman, S

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

Simonet, WS; Lacey, DL; Dunstan, CR

Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro

Yasuda, Η., Shima, Ν;

Mice deficient in osteoproteogens develop early osteoporosis and arterial calcification

Buçay, Ν; Saros, ik; Dunstan, CR

Severe osteoporosis in mice lacking osteoclastogenesis inhibitor/osteoprotegrin

Mizuno, Ah? Amizuka, N; Irie, K

Consensus Development Conference: Diagnosis, Prevention and Treatment of Osteoporosis

Cecil Manual of Medicine

Finkelstein, JS

Bone strength and its determinants

Amman, R; Rizzoli, R

osteoporosis

Orwoll, ES; small, r

Understanding osteoporosis and its treatment

Vogelbos, G

Clinical review 123: Anabolic therapy for osteoporosis

Rosen, CJ; Bilezikian, JP

Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis

Riggs, BL; Hodgson, SF; O'Fallon, WM

A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis

Kleerekoper, M; Peterson, E.L.; Nelson, DA

Treatment of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone mineral density and fracture rate

Ring, JD; Kipshoven, C; Koster, Ah? Ubach, R

Effect of raloxifene in combination with monofluorophosphate compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized controlled trial

Join, YOU Felsenberg, D; Pav, me

A randomized trial of sodium fluoride (60 mg)+/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride. Estrogen coadministration prevents peripheral loss but not vertebral fractures

Gutteridge, DH; Stewart, GAAN; Prins, R.L

Fluoride is no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO study

Meunier, P.J.; Sebert, J.L.; Register, YOU

Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial

Parker, CY; Sachaie, Κ; Adams-Huet, B; Piziak, V; Peterson, RD; Poindexter, JR

New anabolic therapies in osteoporosis

Rubin, MR; Bilezikian, JP

2002 clinical practice guidelines for the diagnosis and treatment of osteoporosis in Canada

Brown, J.P.; Jose, R. G

Do statins prevent both cardiovascular disease and fractures?

Cummings, S.R.; Bauer, DC

Stimulation of bone formation in vitro and in rodents by statins

Mundy, G; Garrett, R; Harris, S

Direction of drug discovery in osteoporosis

Mundy, GR

Effect of simvastatin treatment on bone mineral density and bone metabolism in postmenopausal women with hypercholesterolemia: a 1-year longitudinal study

Montagnani, A; Gonnelli, S; Cepollaro, C

Simvastatin Increases Serum Osteocalcin Concentration in Patients Treated for Hypercholesterolemia

Chan, ΜΗ; Mak, TW; Chiu, RW; Voer, CC; Chan, IH; Lam, CW

Oral statins and increased bone mineral density in postmenopausal women

Edwards, CJ; Hart, Deejay; Spector, TD

Statin Use, Clinical Fractures, and BMD in Postmenopausal Women: Results from the Women's Health Initiative Observational Study

LaCroix, AZ; Cauley, JA; Pettinger, M

Statin use, bone mineral density and fracture risk: the Geelong Osteoporosis Study

Pasco, J. Α.; Kotowicz, MA; Hendrik, M.J.; Sanders, KM; Nicholson, G.C

Relationship between statin use and bone loss: a prospective population-based cohort study in early postmenopausal women

Sirola, J; Honkanen, R; Kroger, H; Jurvelin, JS; Maenpaa, P; Saarikoski, S

Hydroxymethylglutaryl-coenzyme A reductase inhibitors and fracture risk in older women

Chan, KA; Andrade, SE; Boles, M.

HMG-CoA reductase inhibitors and fracture risk

Meier, CR; Schlienger, RG; Kranzlin, ME; Schlegel, B; Jick, H

HMG-CoA reductase inhibitors and risk of hip fracture in elderly patients

Wang, PS; Solomon, DH; Mogun, H; Avorn, J

Statin use and fracture risk

Staa, TP? Wegman, S; Vries, F; Leufkens, B; Kuiper, G

Statin use and fractures: Results of 4 prospective studies and pooled meta-analysis of observational and controlled studies

Bauer, direct current? Mundy, G.R. Jamal, A.E

The effect of a single dose of osteoprotegerin in postmenopausal women

Bekker , PJ ; Holloway , D ; I think, Α; Arrighi , M ; Leese, PT; Dunstan, CR

A randomized controlled trial of ONO-5920 (mindronate/YM529) in Japanese patients with postmenopausal osteoporosis

Morii, Η Nishizawa, Υ Taketani, Υ

The HORIZON Recurrent Fracutre Trial: Clinical Trial Design for the Prevention of Later Fractures After Repair of Low-Trauma Hip Fractures

Colon-Emeric, CS; Caminis , J ; Ζω, ΤΤ

Intravenous injections of ibandronate every three months: a new therapeutic option to prevent bone loss in postmenopausal women

Stakkestad, JA; Benevolenskaya, LI; Stepan, JJ

Lupus disease activity and bone mineral density in women with active lupus: results of a double-blind, multicenter study comparing prasterone with placebo

Petrie, M; Ramsey-Goldman, R; Manzi, S. (1999).

Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxbutyl ester (HCT1026)

Panter , KJ ; Hof , RJ ; Armor, KE; Torbergsen , AC ; Στρατιώτης, P; Ralston, SH

Pharmacological action of a novel potent histoselective benzopyran estrogen

Galbiati, E? Caruso, PL; Amar, G

The use of selective estrogen receptor modulators and selective estrogen receptor modulators in breast cancer

Howell, SJ; Johnston, SR; Howell, A. (1999).

Lasofoxifene is superior to raloxifene in preventing bone loss in postmenopausal women: results after 1 year

Bolognese, M; Mofett, A; Lee, A

Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-ranging studies

Gallagher, JC; Baylink, DJ; ereburger, R; McClung, M

Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss

Rymer, J; Robinson, J.; Fogelman, I

A randomized trial of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures

Studd, J; Arnala, me? Kicovic, PM; Zamblera, D; Kroger, H; Holland, N

Changes in bone mineral density during two years of treatment with tibolone-conjugated estrogens and norgestrel compared with untreated controls in postmenopausal women

Milner, M; Harrison, RF; Gilligan, Hu? Kelly, A

A synthetic peptide fragment of human MERE stimulates new bone formation in vitro and in vivo

Hayashibara, T, Hiraga, T, Yi, B

Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.

Hodsman, AB; Hanley, D.A.; Ettinger, MP

Apomin, a novel hypocholesterolemic agent, accelerates the breakdown of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low-density lipoprotein receptor activity

Roitelman, J; Masson, D; Avner, R.

Musculoskeletal Effects of Recombinant Human IGF-I/IGF Binding Protein-3 Complex in Osteoporotic Patients with Proximal Femoral Fracture: A Double-Blind, Placebo-Controlled Pilot Study

Boonen, S; Rosen, C; Bouillon, R

The effects of strontium ranelate on the risk of vertebral fractures in postmenopausal women with osteoporosis

Meunier, PJ; Roux, C; Seeman, Ε

AMG 162, an anti-rankl monoclonal antibody, induces a rapid, profound, and sustained reduction in bone turnover after a single dose in postmenopausal women

Bekker, PJ; Holloway, DL; Rasmussen, AS

In postmenopausal women, rapid and profound suppression of bone turnover is observed over 6 months in postmenopausal women with a single subcutaneous dose of AMG 162

Bekker, PJ; Holloway, DL; Rasmussen, AS

Serum concentrations of AMG 162 were maintained and bone resorption suppressed for 9 months after a single subcutaneous dose in healthy postmenopausal women

Peterson, MC; Raak, BJ; Chen, D

The role of prostaglandins in the regulation of bone metabolism

Kawaguchi, Η; Pilbeam, CC; Harrison, JR; Raisz, LG

Nitric oxide and bones

Hof, RJ; Ralston, SH

New treatments for osteoporosis

Biskobing, DM

Nitric oxide-releasing NASAIDs: an overview of their current status

Fiorucci, S; Antonelli, Hu? Burgaud, JL; Morelli, A

Design of potent, selective and orally bioavailable cysteine ​​protease cathepsink inhibitors

Tavares, FX; Boncek, V; Deton, DN

osteoporosis

Wuster, C; Rosen, G

Association between isulin-like growth factor 1 and bone mineral density in elderly women and men: the Framingham Heart Study

Langlois, JA; Rosen, C.J.; Vides, M

Low serum IGF-1 and incidence of osteoporotic fractures in postmenopausal women

Gamero, P; Sornay-Listen, E; Delmas, P.D

Effects of recombinant insulin-like growth factor-I and growth hormone on bone metabolism in elderly women.

Ghiron, LJ; Thompson, JL; Holloway, L

short-term effects of recombinant human insulin-like growth factor 1 on bone metabolism in normal women

Ebeling, PR; Jones, JD; O'Fallon, WM; Janes, CH; Riggs, BL

Bone-specific drug delivery systems: Approaches through chemical modification of bone-seeking agents

Hirabayashi, H Fujisaki, J

Will reducing bone malformation increase bone mass?: PPAR gamma2 as a key target in the treatment of age-related bone loss

Duke, G

alpha(n)beta(3) Integrin antagonists as inhibitors of bone resorption

Hartman, GD; Dugan, ME

Nonpeptidic alpha-3 antagonists. 8. In vitro and in vivo evaluation of a potent alpha-beta 3 antagonist for the prevention and treatment of osteoporosis

Hutchinson, JH; Halczenko, W; Brashear, KM

Shik kinase activity is essential for osteoclast function

Miyazaki, Τ; Sanjay , Α ; Neff , L ; Tanaka, S; Horn, WC; Baron, R. (1999).

Reduced expression of c-Src enhances osteoblast differentiation and bone formation

Marzia, M; Sins, NA; Voit, S

New bone-targeting Src tyrosine kinase inhibitor drug discovery

Shakespear, WC; Metcalf, CA; Wang, Y

A novel bone-targeted SRC tyrosine kinase inhibitor, AP23451, prevents bone loss in vitro and in vivo

Boyce, man? Xing, L; Bain, S

Ibandronate: new options in the treatment of osteoporosis

Adami, S; Viapiana, O

osteoporosis

Stoch, SA; Chorev, M; Rosenblatt, M